Table 1.
Main clinical features and indications for treatment in osteopetrosis.
Gene | Autosomal recessive osteopetrosis | Overall disease severity | Hematological defects | Visual defects | Hypocalcemia | Growth retardation | Primary neurodegeneration | Indication to HSCT |
---|---|---|---|---|---|---|---|---|
TCIRG1 | Osteoclast-rich form | Most often severe | Severe | Mild to severe | Severe | Mild to severe | No | Yes |
ClCN7 | Osteoclast-rich form | Severe to mild | Mild to severe | Mild to severe | Severe | Mild to severe | Yes | To be evaluated based on the severity of CNS involvement |
OSTM1 | Osteoclast-rich form | Severe | Mild to severe | Mild to severe | Moderate | Mild to severe | Yes | No severe CNS involvement |
SNX10 | Osteoclast-rich form | Variable | Severe | Severe | Mild | Mild | No | Yes |
CAII | Osteoclast-rich form | Moderate | None | Mild | Mild | Moderate | Cerebral calcification | To be evaluated based on cerebral calcification |
PLEKHM1 | Osteoclast-rich form | Mild | None | None | None | None to moderate | No | No mild presentation |
FERMT3 | Osteoclast-rich form | Severe | Severe | Mild | Mild | Mild | No | Yes |
NEMO | Osteoclast-rich form | Severe | Severe | None | Mild | Moderate | No | Yes |
TNFRSF11A/RANK | Osteoclast-poor form | Most often severe | Mild | Mild | Mild | Moderate | No | Yes |
TNFSF11/RANKL | Osteoclast-poor form | Intermediate | Mild | Mild | Mild | Severe | No | No |